Germany's AMNOG framework should have forced a public net price for iptacopan by mid-2025. None has surfaced, and that absence is the pricing-cascade risk this model exists to flag before launch sequencing locks it in.
Germany's AMNOG process normally forces price discipline through publication. A negotiated Erstattungsbetrag is set within six months of the G-BA's benefit decision and published in the Lauer-Taxe, the price database at least fifteen countries reference when setting their own reimbursement. Iptacopan cleared its G-BA review on 19 December 2024 with a substantial quality-of-life finding, real negotiating leverage for GKV-Spitzenverband. We searched GKV-Spitzenverband's public negotiation registry and Lauer-Taxe references directly. No published net price for Fabhalta in Germany surfaced. Since 2025, manufacturers can opt into the MFG mechanism: a confidential reimbursement amount, paid alongside a fixed additional discount, that never reaches the Lauer-Taxe at all.
That gap matters beyond Germany's own market. Fifteen countries, including France, Italy, Spain, and the UK, still reference Germany's published price in their own reimbursement formulas. A confidential German price breaks that chain entirely, exactly the outcome a manufacturer would want for an ultra-rare, ultra-priced orphan drug. Our price ladder models both branches explicitly: one where Germany's price stays public and anchors the ERP basket, one where MFG confidentiality decouples Germany from the cascade. The launch sequencing recommendation changes materially between the two. Any pricing strategy that assumes only one branch is incomplete before it starts.
Germany PNH pricing — the public-price branch versus the confidential MFG branch
| Price Component | Public-Price Branch | Confidential (MFG) Branch |
|---|---|---|
| List price at launch | Set freely for first 6 months (GKV-FinStG shortened window) | Same free-pricing window applies regardless |
| Negotiated Erstattungsbetrag | Published in Lauer-Taxe, referenceable by 15 IRP-basket countries | Confidential; discount plus additional 9% applied, invisible to Lauer-Taxe |
| ERP cascade risk | High — a low negotiated price can propagate to France, Italy, Spain, UK, and 11 others | Structurally removed; Germany decouples from the referencing chain |
| Manufacturer eligibility | Default path unless MFG elected | Requires R&D-presence criteria; election window open through 30 June 2028 |
Sources: GKV-Spitzenverband §130b SGB V negotiation registry; G-BA Nutzenbewertungsverfahren Iptacopan (Beschluss 19.12.2024); Simon-Kucher analysis of the GKV-FinStG and MFG reforms; moatrx-germany geo-skill IRP-basket country list.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- MFG confidential-pricing mechanism mechanics
- the 2025 reform timeline
- ERP cascade-risk modelling under both public and confidential branches
Delivers
- Germany's IRP-basket membership list
- cascade-risk quantification
- launch-sequencing implications for markets that reference Germany
Delivers
- The interaction between §35a orphan auto-benefit and negotiation leverage
- GKV-Spitzenverband's negotiating position under a substantial-benefit finding
- whether MFG confidentiality changes the negotiation dynamic itself
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the missing Lauer-Taxe price is the single variable that decides whether any German launch-sequencing plan holds up
- Stated as a claim and pressure-tested before the rest of the model is built out
- The free-pricing window, the GKV-FinStG's shortened six-month clock, and the retroactive repayment mechanic
- Where Germany's mechanism differs from a WAC-based or ex-factory-only market
- What the §35a orphan pathway changes about the negotiation starting point
- The 15 countries that reference Germany's published price, named market by market
- How a confidential MFG price breaks the cascade, and who is exposed if it doesn't
- Modelling both branches side by side, not picking one
- US WAC and EU list-price anchors for eculizumab, ravulizumab, and crovalimab
- What the analogue class supports for iptacopan's own price defence
- QALY-based value price against Germany's orphan-adjusted willingness-to-pay range
- Where the quality-of-life evidence is strong enough to defend a premium
- Statutory, negotiated, channel, and access components decomposed line by line
- How the waterfall itself changes shape once MFG confidentiality applies
- Sequencing recommendation under each branch, with the cascade risk priced in
- Conservative, base, and aggressive revenue scenarios, and which assumptions move them most
- The open pricing questions your team must close before the launch price is locked
- Structured by function, ready for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources (G-BA, GKV-Spitzenverband, EMA) and live reimbursement-database checks — not secondary summaries. Findings are independently verified before inclusion.
PNH Germany pricing sources: G-BA Nutzenbewertungsverfahren decision pages, GKV-Spitzenverband's §130b negotiation registry, and published analysis of the GKV-FinStG and MFG pricing reforms.
- G-BA Beschluss date and benefit category verified against the live G-BA Nutzenbewertungsverfahren page for iptacopan
- Absence of a published Lauer-Taxe net price verified via direct search of GKV-Spitzenverband's public negotiation registry
- MFG confidential-pricing mechanism and 2028 election deadline verified against published reform analysis
- Germany's 15-country IRP-basket membership verified against published reform analysis naming each referencing country
Frequently asked questions
Commission this model
AXLRx delivers PNH pricing strategy models built for market access and pricing teams navigating AMNOG, IRP cascade risk, and confidential-pricing scenarios. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.